bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 2 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas
Authors: Wakimoto Hiroaki , Tanaka Shota , Curry William T. , Loebel Franziska , Zhao Dan , Tateishi Kensuke , Chen Juxiang , Klofas Lindsay K. , Lelic Nina , Kim James C. , Dias-Santagata Dora , Ellisen Leif W. , Borger Darrell R. , Fendt Sarah-Maria , Vander Heiden Matthew G. , Batchelor Tracy T. , Iafrate A. John , Cahill Daniel P. , Chi Andrew S.
Published: April 2023

XLS file - 24KB, Supplementary Table S2. Primers used for sequencing.
Supplementary Figure 3 from Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
Authors: Italiano Antoine , Lagarde Pauline , Brulard Céline , Terrier Philippe , Laë Marick , Marques Bernard , Ranchere-Vince Dominique , Michels Jean-Jacques , Trassard Martine , Cioffi Angela , Piperno-Neumann Sophie , Chevreau Christine , Blay Jean-Yves , Delcambre Corinne , Isambert Nicolas , Penel Nicolas , Bay Jacques-Olivier , Bonvalot Sylvie , Le Cesne Axel , Coindre Jean-Michel , Chibon Frédéric
Published: April 2023

PDF file - 52K, Kaplan-Meier curves of overall survival according to age (A), tumor size (B), tumor location (C) and tumor grade (D)
Supplementary Figure 2 from Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
Authors: Italiano Antoine , Lagarde Pauline , Brulard Céline , Terrier Philippe , Laë Marick , Marques Bernard , Ranchere-Vince Dominique , Michels Jean-Jacques , Trassard Martine , Cioffi Angela , Piperno-Neumann Sophie , Chevreau Christine , Blay Jean-Yves , Delcambre Corinne , Isambert Nicolas , Penel Nicolas , Bay Jacques-Olivier , Bonvalot Sylvie , Le Cesne Axel , Coindre Jean-Michel , Chibon Frédéric
Published: April 2023

PDF file - 55K, Kaplan-Meier curves of metastasis-free survival according to tumor site (A), tumor size (B), tumor location (C) and tumor grade (D)
Supplementary Fig.3 from Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Authors: Perna Serena K. , Pagliara Daria , Mahendravada Aruna , Liu Hao , Brenner Malcolm K. , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

PDF file 77K, IL7Ra.CAR-GD2 CTLs were stimulated with EBV-LCLs (ratio 1:1 or 1:2) and then 2 hours later we detected the production of IL-2 by intracellular staining and FACS analysis. CTLs without antigen stimulation and PMA/Ionomycin and Staphylococcus Exotoxin were used as negative and positive controls, respectively
Supplementary Fig.2 from Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Authors: Perna Serena K. , Pagliara Daria , Mahendravada Aruna , Liu Hao , Brenner Malcolm K. , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

PDF file 66K, CD3+ cells obtained after magnetic depletion of CD19, CD14 and CD56 positve cells were stimulated for 15 minutes either with IL-2 or IL-7 and then analyzed for STAT5 phosphorylation. Upper panels indicate the expression of IL-7Ra by CD3+ cells at the time of incubation with the cytokines
Supplementary Fig.1 from Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Authors: Perna Serena K. , Pagliara Daria , Mahendravada Aruna , Liu Hao , Brenner Malcolm K. , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Supplementary Fig.1 PDF file 106K, A. Gating strategy to evaluate the transduction efficiency for the CAR-GD2. The gate was drawn based on the physical parameters and the expression of the CAR-GD2 evaluated on gated cells. B. Gating strategy to evaluate the transduction efficiency for IL-7Ra. The gate was drawn based on the physical parameters and the expression of IL-7Ra evaluated on gated cells. C. Gating strategy to evaluate the phosphorylation of STAT5. The gate was drawn based on the physical parameters and the phosphorylation of STAT5 evaluated on gated cells. D. Gating strategy to assess CSFE dilution. After gating on lymphocyte, the dilution of the CFSE was assessed on CD8+ cells. Two independent experiments are shown. E. Gating strategy to assess the elimination of tumor cells in co-culture experiments. The gate was drawn based on the physical parameters. Lymphocytes were identified based on CD3 expression and tumor cells by GFP expression on gated cells
Supplementary Figures 1 - 3 from Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
Authors: Roh Ju-Won , Huang Jie , Hu Wei , Yang XiaoYun , Jennings Nicholas B. , Sehgal Vasudha , Sohn Bo Hwa , Han Hee Dong , Lee Sun Joo , Thanapprapasr Duangmani , Bottsford-Miller Justin , Zand Behrouz , Dalton Heather J. , Previs Rebecca A. , Davis Ashley N. , Matsuo Koji , Lee Ju-Seog , Ram Prahlad , Coleman Robert L. , Sood Anil K.
Published: April 2023

PDF file - 959KB, Supplementary Figure 1. PDGFRalpha expression and activation in patients with uterine cancer. Supplementary Figure 2. In vivo therapeutic and biological effects of PDGFRalpha blockade (3G3) on uterine cancer. Supplementary 3. Network analysis of angiogenesis factors down-regulated by 3G3 treatment in PDGFRalpha-positive cells and PDGFRalpha-negative cells.
Supplementary Methods from Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy
Authors: Chandramohan Vidyalakshmi , Bao Xuhui , Keir Stephen T. , Pegram Charles N. , Szafranski Scott E. , Piao Hailan , Wikstrand Carol J. , McLendon Roger E. , Kuan Chien-Tsun , Pastan Ira H. , Bigner Darell D.
Published: April 2023

Supplementary Methods - PDF file 94K, The supplementary methods section describes the following: Construction, expression and purification of different EGFRvIII deletion mutants, cloning of variable heavy (VH) and variable light (VL) domains of P588 and D2C7 mAb, surface plasmon resonance, stability assay, and immunohistochemistry of frozen D270MG brain tumor tissue
Supplementary Figure Legend from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis
Authors: Touil Yasmine , Igoudjil Wassila , Corvaisier Matthieu , Dessein Anne-Frédérique , Vandomme Jérôme , Monté Didier , Stechly Laurence , Skrypek Nicolas , Langlois Carole , Grard Georges , Millet Guillaume , Leteurtre Emmanuelle , Dumont Patrick , Truant Stéphanie , Pruvot François-René , Hebbar Mohamed , Fan Fan , Ellis Lee M. , Formstecher Pierre , Van Seuningen Isabelle , Gespach Christian , Polakowska Renata , Huet Guillemette
Published: April 2023

PDF file - 50K
Supplementary Figure 1 from DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett's Esophagus
Authors: Alvi Muhammad A. , Liu Xinxue , O'Donovan Maria , Newton Richard , Wernisch Lorenz , Shannon Nicholas B. , Shariff Kareem , di Pietro Massimiliano , Bergman Jacques J.G.H.M. , Ragunath Krish , Fitzgerald Rebecca C.
Published: April 2023

PDF file - 20K,Internal validation for ATP2B4
Supplementary Appendix 2 from Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume
Authors: Rockall Andrea G. , Avril Norbert , Lam Raymond , Iannone Robert , Mozley P. David , Parkinson Christine , Bergstrom Donald , Sala Evis , Sarker Shah-Jalal , McNeish Iain A. , Brenton James D.
Published: April 2023

PDF file - 51KB, Acquisition parameters for PET and CT.
Supplemental Materials and Methods from Mesenchymal Stem Cells from Human Fat Engineered to Secrete BMP4 Are Nononcogenic, Suppress Brain Cancer, and Prolong Survival
Authors: Li Qian , Wijesekera Olindi , Salas Sussan J. , Wang Joanna Y. , Zhu Mingxin , Aprhys Colette , Chaichana Kaisorn L. , Chesler David A. , Zhang Hao , Smith Christopher L. , Guerrero-Cazares Hugo , Levchenko Andre , Quinones-Hinojosa Alfredo
Published: April 2023

Supplemental Materials and Methods from Mesenchymal Stem Cells from Human Fat Engineered to Secrete BMP4 Are Nononcogenic, Suppress Brain Cancer, and Prolong Survival
Supplementary Figure 4 from Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Authors: Xiang Qingfeng , Chen Weiqiang , Ren Meng , Wang Jingnan , Zhang Hongwu , Deng David Y.B. , Zhang Lei , Shang Changzhen , Chen Yajin
Published: April 2023

PDF file - 52K, Cabozantinib inhibits receptor tyrosine kinases (RTKs) signaling in vivo.
Supplementary Figure 1 from Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Authors: Xiang Qingfeng , Chen Weiqiang , Ren Meng , Wang Jingnan , Zhang Hongwu , Deng David Y.B. , Zhang Lei , Shang Changzhen , Chen Yajin
Published: April 2023

PDF file - 54K, Sorafenib-resistant HCC specimens exhibit higher p-MET-positive rate compared with sorafenib-sensitive HCC specimens.
Data Supplement from Mesenchymal Stem Cells from Human Fat Engineered to Secrete BMP4 Are Nononcogenic, Suppress Brain Cancer, and Prolong Survival
Authors: Li Qian , Wijesekera Olindi , Salas Sussan J. , Wang Joanna Y. , Zhu Mingxin , Aprhys Colette , Chaichana Kaisorn L. , Chesler David A. , Zhang Hao , Smith Christopher L. , Guerrero-Cazares Hugo , Levchenko Andre , Quinones-Hinojosa Alfredo
Published: April 2023

Data Supplement from Mesenchymal Stem Cells from Human Fat Engineered to Secrete BMP4 Are Nononcogenic, Suppress Brain Cancer, and Prolong Survival
Supplementary Figure 4 from microRNA-224 Promotes Cell Proliferation and Tumor Growth in Human Colorectal Cancer by Repressing PHLPP1 and PHLPP2
Authors: Liao Wen-Ting , Li Ting-Ting , Wang Zheng-Gen , Wang Shu-Yang , He Mei-Rong , Ye Ya-Ping , Qi Lu , Cui Yan-Mei , Wu Ping , Jiao Hong-Li , Zhang Chi , Xie Yi-Jun , Wang Jun-Xian , Ding Yan-Qing
Published: April 2023

Supplementary Figure 4 - PDF file 157K, Supplementary Fig.S4. Correlations between miR-224 and PHLPP1 and PHLPP2 expression in clinical CRC tissue samples
Supplementary Figure 3 from microRNA-224 Promotes Cell Proliferation and Tumor Growth in Human Colorectal Cancer by Repressing PHLPP1 and PHLPP2
Authors: Liao Wen-Ting , Li Ting-Ting , Wang Zheng-Gen , Wang Shu-Yang , He Mei-Rong , Ye Ya-Ping , Qi Lu , Cui Yan-Mei , Wu Ping , Jiao Hong-Li , Zhang Chi , Xie Yi-Jun , Wang Jun-Xian , Ding Yan-Qing
Published: April 2023

Supplementary Figure 3 - PDF file 63K, Supplementary Fig.S3. Overexpression of PHLPP1 or PHLPP2 abrogated the miR-224-mediated regulation of of the cell-cycle regulators
Supplementary Figure S7 from Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma
Authors: Lee Hye Won , Park Young Mi , Lee Se Jeong , Cho Hyun Jung , Kim Duk-Hwan , Lee Jung-Il , Kang Myung-Soo , Seol Ho Jun , Shim Young Mog , Nam Do-Hyun , Kim Hyeon Ho , Joo Kyeung Min
Published: April 2023

PDF file - 105K, Supplementary Figure S7. Metastatic activities of H322 cells were suppressed by ACTA2 silencing through downregulation of FAK and c-MET (A, B) To investigate the effect of ACTA2 silencing on migration and invasion, H322 cells were transfected with ACTA2-specific siRNA. 48 hours post-transfection, whole cell lysates and total RNA were prepared to determine the protein and mRNA level of ACTA2, FAK, c-MET, E-cadherin, and vimentin by Western blot and RT-qPCR, respectively. (C) Cells were transfected with indicated siRNA and after 24-hours incubation, cells were resuspended into 12-well plate. Migratory activity was determined by measuring migrated distance. (D) Transfected cells were added into Matrigel Transwell; after 24 hours, invading cells were stained and counted under microscope. *, P<0.05.
Supplementary Figure S6 from Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma
Authors: Lee Hye Won , Park Young Mi , Lee Se Jeong , Cho Hyun Jung , Kim Duk-Hwan , Lee Jung-Il , Kang Myung-Soo , Seol Ho Jun , Shim Young Mog , Nam Do-Hyun , Kim Hyeon Ho , Joo Kyeung Min
Published: April 2023

Supplementary Figure S6 - PDF file 30K, Supplementary Figure S6. Silencing of FAK and c-MET by specific siRNAs in PC14PE6 (A) and H322 (B) cells To investigate whether ACTA2 silencing inhibited migratory and invasive activity by suppressing FAK and c-MET expression, silencing of FAK and c-MET using specific siRNA was checked. PC14PE6 and H322 cells were transfected with each siRNA using Lipofectamine2000; 48 hours post-transfection, whole cell lysates were prepared and the level of FAK and c-MET was determined by Western blot
Supplementary Figure S5 from Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma
Authors: Lee Hye Won , Park Young Mi , Lee Se Jeong , Cho Hyun Jung , Kim Duk-Hwan , Lee Jung-Il , Kang Myung-Soo , Seol Ho Jun , Shim Young Mog , Nam Do-Hyun , Kim Hyeon Ho , Joo Kyeung Min
Published: April 2023

Supplementary Figure S5 - PDF file 56K, Supplementary Figure S5. Effect of ACTA2 silencing using independent shRNA on expression of FAK and c-MET in PC14PE6 cells To investigate whether ACTA2 silencing decreased expression of FAK and c-MET, PC14PE6 cells were transfected with several ACAT2 shRNA using Lipofectamine2000. 48 hours post-transfection, whole cell lysates were prepared to detect the protein and mRNA level of FAK and c-MET by Western blot and RT-qPCR, respectively
Supplementary Figure S2 from Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma
Authors: Lee Hye Won , Park Young Mi , Lee Se Jeong , Cho Hyun Jung , Kim Duk-Hwan , Lee Jung-Il , Kang Myung-Soo , Seol Ho Jun , Shim Young Mog , Nam Do-Hyun , Kim Hyeon Ho , Joo Kyeung Min
Published: April 2023

Supplementary Figure S2 - PDF file 183K, Supplementary Figure S2. Generation of stable cells expressing ACTA2 shRNA. To establish stable cells expressing ACTA2 shRNA vector, PC14PE6 cells were transfected with each ACTA2 shRNA vector (shACTA2) or empty pLKO vector (shCTRL) Stable cells were selected by culturing with puromycin. ACTA2 mRNA level was determined by RT-qPCR. Migration and invasion of shACTA2 was checked by wound closure assay and Matrigel transwell assay, respectively, and represented relative migration and invasion as compared to shCTRL
Supplementary Figure Legends from Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma
Authors: Lee Hye Won , Park Young Mi , Lee Se Jeong , Cho Hyun Jung , Kim Duk-Hwan , Lee Jung-Il , Kang Myung-Soo , Seol Ho Jun , Shim Young Mog , Nam Do-Hyun , Kim Hyeon Ho , Joo Kyeung Min
Published: April 2023

Supplementary Figure Legends - PDF file 75K, Supplementary figure legends
Supplementary Figure 4C from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Authors: Breunig Christian , Mueller Bernadett J. , Umansky Ludmila , Wahl Kristin , Hoffmann Katrin , Lehner Frank , Manns Michael P. , Bantel Heike , Falk Christine S.
Published: April 2023

(C) To detect the proliferation/adhesion profile of HepG2, Hep3B and Huh-7 cells were grown 24h prior treatment (-24h) with 5 (dark gray line) or 10µM (black line) of PLX4720, U0126, AZD6244, PD0325901or 6.5 and 13µM sorafenib and DMSO as control (light gray line) for up to 96h while the cell index (CI, relative change in electrical impedance of the cells) was measured in real time every 4h and normalized to the start-point at treatment (0h, CI=1). The Asterisks indicate no measurement of 10µM PD0325901 in all three cell lines and 10µM PLX4720 in Huh-7.
Supplementary Figure 4A, B from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Authors: Breunig Christian , Mueller Bernadett J. , Umansky Ludmila , Wahl Kristin , Hoffmann Katrin , Lehner Frank , Manns Michael P. , Bantel Heike , Falk Christine S.
Published: April 2023

Apoptosis induction and Proliferation/adhesion profiles of HCC cell lines treated with MAPK inhibitors. Detection of apoptosis by measuring the sub-G1 peak using propidium iodide in HepG2 (left), Hep3B (middle) and Huh-7 (right) cells treated with DMSO, 5 (A) or 10µM (B) MAPK inhibitor or 6.5 (A) and 13µM (B) sorafenib for 48 and 96h respectively (n{greater than or equal to}3 {plus minus} SD). Mean and {plus minus}SD from n{greater than or equal to}2 experiments.
Supplementary Information from A Peptide-Based Positron Emission Tomography Probe for In Vivo Detection of Caspase Activity in Apoptotic Cells
Authors: Hight Matthew R. , Cheung Yiu-Yin , Nickels Michael L. , Dawson Eric S. , Zhao Ping , Saleh Samir , Buck Jason R. , Tang Dewei , Washington M. Kay , Coffey Robert J. , Manning H. Charles
Published: April 2023

PDF file - 165KB, Supplemental Materials and Methods, Figure Legends.
Supplementary Figure 3A from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Authors: Breunig Christian , Mueller Bernadett J. , Umansky Ludmila , Wahl Kristin , Hoffmann Katrin , Lehner Frank , Manns Michael P. , Bantel Heike , Falk Christine S.
Published: April 2023

Alteration of total protein amount of MEK1, ERK1/2, c-Jun, Akt and ATF2 by MAPK inhibition. Total amount of MEK1, ERK1/2, c-Jun, Akt and ATF2 of HepG2 (A), Hep3B (B) and Huh-7 (C) cells after treatment with 0.2, 1 or 5µM sorafenib, PLX4720, U0126, AZD6244, PD0325901, GW5074 or sunitinib at different time points.
Supplementary Figure 2B from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Authors: Breunig Christian , Mueller Bernadett J. , Umansky Ludmila , Wahl Kristin , Hoffmann Katrin , Lehner Frank , Manns Michael P. , Bantel Heike , Falk Christine S.
Published: April 2023

(B) The phosphorylation of the given proteins in lysates of HepG2 (left), Hep3B (middle) and Huh-7 (right) cells after treatment with 0.2, 1, and 5µM GW5074 or sunitinib at different time points. The values represent MFI of 30-60 beads for each kinase and time point. One of two or three representative experiments is shown.
Supplementary Figure 2A from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Authors: Breunig Christian , Mueller Bernadett J. , Umansky Ludmila , Wahl Kristin , Hoffmann Katrin , Lehner Frank , Manns Michael P. , Bantel Heike , Falk Christine S.
Published: April 2023

Effects of MAPK inhibitors on JNK, c-Jun, Akt and ATF2 phosphorylation. (A) Kinetics of p-JNK, p-c-Jun, p-Akt and p-ATF2 phosphorylation in HepG2 (left) and Hep3B (right) cell lines after treatment with 6.5µM sorafenib, 5µM AZD6244, U0126 (left) or 5µM PLX4720, PD0325901 (right) or DMSO at the given time points are displayed as MFI.
Supplementary Figure 1 from A Peptide-Based Positron Emission Tomography Probe for In Vivo Detection of Caspase Activity in Apoptotic Cells
Authors: Hight Matthew R. , Cheung Yiu-Yin , Nickels Michael L. , Dawson Eric S. , Zhao Ping , Saleh Samir , Buck Jason R. , Tang Dewei , Washington M. Kay , Coffey Robert J. , Manning H. Charles
Published: April 2023

PDF file - 79KB, 19FFB-VAD-FMK and parent peptide enzyme selectivity. Biochemistry, fluorescence measured IC50 values, collected as duplicates, of the parent peptide, VAD-FMK, and 19FFB-VAD-FMK against caspases-3/6/7/8.
Supplementary Table 2 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
Authors: Zhao Qi , Caballero Otavia L. , Davis Ian D. , Jonasch Eric , Tamboli Pheroze , Yung W.K. Alfred , Weinstein John N. , Strausberg Robert L. , Yao Jun
Published: April 2023

XLSX file - 75K, Computational prediction of FGFR2 IIIb/c isoforms in normal kidney and ccRCC
CCR Translation for This Article from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo
Authors: Renshaw Jane , Taylor Kathryn R. , Bishop Ryan , Valenti Melanie , De Haven Brandon Alexis , Gowan Sharon , Eccles Suzanne A. , Ruddle Ruth R. , Johnson Louise D. , Raynaud Florence I. , Selfe Joanna L. , Thway Khin , Pietsch Torsten , Pearson Andrew D. , Shipley Janet
Published: April 2023

CCR Translation for This Article from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo
Supplementary Figure 3 from Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Authors: Liang Ji , Piao Yuji , Holmes Lindsay , Fuller Gregory N. , Henry Verlene , Tiao Ningyi , de Groot John F.
Published: April 2023

PDF file 429K, S100A4 expression in glioma tumors
Supplementary Table S3 from Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response
Authors: Gao Qiong , Patani Neill , Dunbier Anita K. , Ghazoui Zara , Zvelebil Marketa , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

This details the genes that have been associated with proliferation identified by use of gene ontology (GO), cell cycle related genes and proliferation clusters.
Supplementary Table 2 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
Authors: Yin Xuefeng , Luistro Leopoldo , Zhong Hua , Smith Melissa , Nevins Tom , Schostack Kathleen , Hilton Holly , Lin Tai-An , Truitt Theresa , Biondi Denise , Wang Xiaoqian , Packman Kathryn , Rosinski Jim , Berkofsky-Fessler Windy , Tang Jian-Ping , Pant Saumya , Geho David , Vega-Harring Suzana , DeMario Mark , Levitsky Hy , Simcox Mary
Published: April 2023

XLS file, 33K, Summary of RG7212 monotherapy and combination antitumor efficacy.
Supplementary Materials and Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Tabernero Josep , Markman Ben , Patnaik Amita , Tolcher Anthony W. , Baselga José , Shi Weiliang , Egile Coumaran , Ruiz-Soto Rodrigo , Laird A. Douglas , Miles Dale , LoRusso Patricia M.
Published: April 2023

PDF file - 123KB
Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Tabernero Josep , Markman Ben , Patnaik Amita , Tolcher Anthony W. , Baselga José , Shi Weiliang , Egile Coumaran , Ruiz-Soto Rodrigo , Laird A. Douglas , Miles Dale , LoRusso Patricia M.
Published: April 2023

PDF file - 49KB
Supplementary Figure 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Tabernero Josep , Markman Ben , Patnaik Amita , Tolcher Anthony W. , Baselga José , Shi Weiliang , Egile Coumaran , Ruiz-Soto Rodrigo , Laird A. Douglas , Miles Dale , LoRusso Patricia M.
Published: April 2023

PDF file - 4775KB, Supplementary Figure 3. Reduction in Extracellular Signal-Regulated Kinase (ERK) Pathway Signaling by SAR245409 in Paired Tumor Biopsies.
Supplementary Table 2 from BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
Authors: Mar Victoria J. , Wong Stephen Q. , Li Jason , Scolyer Richard A. , McLean Catriona , Papenfuss Anthony T. , Tothill Richard W. , Kakavand Hojabr , Mann Graham J. , Thompson John F. , Behren Andreas , Cebon Jonathan S. , Wolfe Rory , Kelly John W. , Dobrovic Alexander , McArthur Grant A.
Published: April 2023

Supplementary Table 2 - PDF file 16632K, Single nucleotide variants identified for each sample
Supplementary File from Integrated MicroRNA Network Analyses Identify a Poor-Prognosis Subtype of Gastric Cancer Characterized by the miR-200 Family
Authors: Song Fengju , Yang Da , Liu Ben , Guo Yan , Zheng Hong , Li Lian , Wang Tao , Yu Jinpu , Zhao Yanrui , Niu Ruifang , Liang Han , Winkler Hans , Zhang Wei , Hao Xishan , Chen Kexin
Published: April 2023

PDF file 1705K, Supplementary methods, tables, and figures Supplemental Table 1. Characteristics of the 385 GC cases included in the study Supplemental Table 2. Identification of key microRNAs associated with GC survival Supplemental Table 3. Univariate and multivariate Cox proportional hazard model comparing expression of four key microRNAs with survival in GCa Supplemental Table 4. Univariate and multivariate Cox proportional hazard model of the expression of 11 EMT markers and survival in GCa Supplemental Figure 1. Identification of two gastric cancer microRNA subtypes Supplemental Figure 2. Representative qRT-PCR results for miR-200a, miR-200b, and miR-125b Supplemental Figure 3. Validation of the mesenchymal and epithelial subtypes in an independent population from Singapore. Supplemental Figure 4. Validation of the association between key microRNA expression and GC survival Supplemental Figure 5. (A) Forced miR-200b expression decreased ZEB1 expression and markedly decreased the expression of mesenchymal markers vimentin and N-cadherin. (B) N-cadherin/ZEB1 staining of MGC-803 and SGC-7901 cells transfected with miR-200b or miR-Ctrl for 72 hours Cell nuclei were stained with DAPI
Supplementary Methods from Telomere Content and Risk of Second Malignant Neoplasm in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Authors: Gramatges Maria M. , Liu Qi , Yasui Yutaka , Okcu M. Fatih , Neglia Joseph P. , Strong Louise C. , Armstrong Gregory T. , Robison Leslie L. , Bhatia Smita
Published: April 2023

PDF file - 62K, Additional detail with regard to the source of DNA and methods for DNA isolation, as well as methods for quantitative PCR in estimating telomere content, are provided.
Supplementary Figures 1 - 4 from Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Authors: Weroha S. John , Becker Marc A. , Enderica-Gonzalez Sergio , Harrington Sean C. , Oberg Ann L. , Maurer Matthew J. , Perkins Sarah E. , AlHilli Mariam , Butler Kristina A. , McKinstry Sarah , Fink Stephanie , Jenkins Robert B. , Hou Xiaonan , Kalli Kimberly R. , Goodman Karin M. , Sarkaria Jann N. , Karlan Beth Y. , Kumar Amanika , Kaufmann Scott H. , Hartmann Lynn C. , Haluska Paul
Published: April 2023

PDF file - 298K, 1) Ki67 IHC staining of patient & Avatars; 2) pan-CK, CD45, vimentin staining of Avatars; 3) graph of gains/losses by aCGH in Avatars; 4) Ca125 levels in serum of patients/Avatars.
Supplementary Figure Legend from Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Authors: Weroha S. John , Becker Marc A. , Enderica-Gonzalez Sergio , Harrington Sean C. , Oberg Ann L. , Maurer Matthew J. , Perkins Sarah E. , AlHilli Mariam , Butler Kristina A. , McKinstry Sarah , Fink Stephanie , Jenkins Robert B. , Hou Xiaonan , Kalli Kimberly R. , Goodman Karin M. , Sarkaria Jann N. , Karlan Beth Y. , Kumar Amanika , Kaufmann Scott H. , Hartmann Lynn C. , Haluska Paul
Published: April 2023

PDF file - 76K
Supplementary Figure 2 from RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
Authors: Rampias T. , Giagini A. , Siolos S. , Matsuzaki H. , Sasaki C. , Scorilas A. , Psyrri A.
Published: April 2023

PDF file - 119KB, Identified HRAS mutations.
Supplementary Table 4 from Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Authors: Pennington Kathryn P. , Walsh Tom , Harrell Maria I. , Lee Ming K. , Pennil Christopher C. , Rendi Mara H. , Thornton Anne , Norquist Barbara M. , Casadei Silvia , Nord Alexander S. , Agnew Kathy J. , Pritchard Colin C. , Scroggins Sheena , Garcia Rochelle L. , King Mary-Claire , Swisher Elizabeth M.
Published: April 2023

PDF file 48K, Genomic regions for targeted capture
Supplementary Table 3 from Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Authors: Pennington Kathryn P. , Walsh Tom , Harrell Maria I. , Lee Ming K. , Pennil Christopher C. , Rendi Mara H. , Thornton Anne , Norquist Barbara M. , Casadei Silvia , Nord Alexander S. , Agnew Kathy J. , Pritchard Colin C. , Scroggins Sheena , Garcia Rochelle L. , King Mary-Claire , Swisher Elizabeth M.
Published: April 2023

PDF file 69K, Paired primary and recurrent carcinomas
Supplementary Data from IL-17A Stimulates the Progression of Giant Cell Tumors of Bone
Authors: Xu Meng , Song Zhi-Gang , Xu Cheng-Xiong , Rong Guang-Hua , Fan Ke-Xing , Chen Ji-Ying , Zhang Wei , Jia Jin-Peng , Han Gang , Wang Wei , Chai Wei , Liang Wen-Tao , Bi Wen-Zhi , Wang Yan
Published: April 2023

Supplementary Data - PDF file 126K, Supplementary Figure S1. The isolation and culture of MNGCs and SCs from GCTB samples. A. After a quick centrifuge, the raw MNGCs were stained with Hoechst 33342 for 1h and sorted by a flow cytometric cell sorter. The MNGCs were huge and contained high levels of DNA and were thus clearly gated and sorted. A representative TRAP staining of the isolated MNGCs was shown. D. SCs were isolated and a representative microscopic morphology was shown. Supplementary Figure S2. Gene microarray and pathway analysis. A, A heat map of genes that are up-regulated over 1.5-fold by IL-17A in IL-17RA+SCs. The IL-17RA+SCs were treated with DMSO or 10 ng/ml IL-17A. After 48 hrs of IL-17A treatment, RNAs were isolated from cells and then subjected to gene microarray analysis.IL-17A pathway in IL-17RA-positive stromal cells. B, Software-assisted identification of pathways affected by IL-17A exposure, as revealed by Ingenuity Pathway Analysis. Differentially-expressed proteins showing a +1.5-fold change or greater were selected and entered into IPA software to illustrate potential interactions. Supplementary Figure S3. Myc and STAT3 inhibitor treatment suppressed IL-17A stimulated cell proliferation and RANKL expression in IL-17RA+SCs. A, The Myc inhibitor 10058-F4 treatment blocked IL-17A stimulated IL-17RA+ SCs proliferation. B, Treatment with the STAT3 inhibitor AG490 blocked IL-17A-induced RANKL mRNA expression in IL-17RA+SCs. The results are expressed as the mean values plus-minus SD. a,b,c,d data not sharing the same letter are significantly different from one another in each group (P < 0.05) by ANOVA and Duncan's multiple range test
Supplementary Table 1 from Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Authors: Pennington Kathryn P. , Walsh Tom , Harrell Maria I. , Lee Ming K. , Pennil Christopher C. , Rendi Mara H. , Thornton Anne , Norquist Barbara M. , Casadei Silvia , Nord Alexander S. , Agnew Kathy J. , Pritchard Colin C. , Scroggins Sheena , Garcia Rochelle L. , King Mary-Claire , Swisher Elizabeth M.
Published: April 2023

PDF file 80K, Cases with deleterious germline mutations, somatic HR mutations, and somatic PTEN mutations
Supplementary Data Legends from IL-17A Stimulates the Progression of Giant Cell Tumors of Bone
Authors: Xu Meng , Song Zhi-Gang , Xu Cheng-Xiong , Rong Guang-Hua , Fan Ke-Xing , Chen Ji-Ying , Zhang Wei , Jia Jin-Peng , Han Gang , Wang Wei , Chai Wei , Liang Wen-Tao , Bi Wen-Zhi , Wang Yan
Published: April 2023

Supplementary Data Legends - PDF file 57K, Figure legends for supplementary data
Supplementary Table 1 from Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials
Authors: Giessen Clemens , Laubender Ruediger Paul , Ankerst Donna Pauler , Stintzing Sebastian , Modest Dominik Paul , Mansmann Ulrich , Heinemann Volker
Published: April 2023

PDF file - 82k, Trials included in the analysis
Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Authors: Baker Sharyn D. , Zimmerman Eric I. , Wang Yong-Dong , Orwick Shelley , Zatechka Douglas S. , Buaboonnam Jassada , Neale Geoffrey A. , Olsen Scott R. , Enemark Eric J. , Shurtleff Sheila , Rubnitz Jeffrey E. , Mullighan Charles G. , Inaba Hiroto
Published: April 2023

PDF file, 28K, Error rates and confidence levels for frequency of detection of FLT3 kinase domain mutations by next generation sequencing.
Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Authors: Baker Sharyn D. , Zimmerman Eric I. , Wang Yong-Dong , Orwick Shelley , Zatechka Douglas S. , Buaboonnam Jassada , Neale Geoffrey A. , Olsen Scott R. , Enemark Eric J. , Shurtleff Sheila , Rubnitz Jeffrey E. , Mullighan Charles G. , Inaba Hiroto
Published: April 2023

PDF file, 33K, Primers used to sequence FLT3 exons 13 to 23.
Supplementary Table 4 from Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Authors: Guinney Justin , Ferté Charles , Dry Jonathan , McEwen Robert , Manceau Gilles , Kao KJ , Chang Kai-Ming , Bendtsen Claus , Hudson Kevin , Huang Erich , Dougherty Brian , Ducreux Michel , Soria Jean-Charles , Friend Stephen , Derry Jonathan , Laurent-Puig Pierre
Published: April 2023

PDF file - 35K, Data sets used for evaluation of the colorectal RAS model, and reported AUC in classification of KRAS mutant from wild-type samples.
Supplementary Table 3 from Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Authors: Guinney Justin , Ferté Charles , Dry Jonathan , McEwen Robert , Manceau Gilles , Kao KJ , Chang Kai-Ming , Bendtsen Claus , Hudson Kevin , Huang Erich , Dougherty Brian , Ducreux Michel , Soria Jean-Charles , Friend Stephen , Derry Jonathan , Laurent-Puig Pierre
Published: April 2023

PDF file - 43K, Top RAS model genes.
Supplementary Figure 9 from Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors
Authors: Wu Chao-Yi , Yang Li-Hua , Yang Huang-Yu , Knoff Jayne , Peng Shiwen , Lin Yi-Hsin , Wang Chenguang , Alvarez Ronald D. , Pai Sara I. , Roden Richard B.S. , Hung Chien-Fu , Wu T-C
Published: April 2023

PDF file - 2078K, Characterization of antigen-specific CD8+ T cells immune responses and antitumor effects in TC-1 tumor-bearing mice treated with radiation therapy and intratumoral vaccination with OVA peptide.
Supplementary Figure 5 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Authors: Valentino Joseph D. , Li Jing , Zaytseva Yekaterina Y. , Mustain W. Conan , Elliott Victoria A. , Kim Ji Tae , Harris Jennifer W. , Campbell Katherine , Weiss Heidi , Wang Chi , Song Jun , Anthony Lowell , Townsend Courtney M. , Evers B. Mark
Published: April 2023

PDF file - 1080KB, Combination PI3K + MEK inhibition enhances apoptosis compared to monotherapy. (A) NCI-H727 and (B) QGP-1 cells were plated in 24 well plates at a density of 5x104 cells/cm2. Treatments were initiated the following morning with either control, BKM120 (5 μM), PD0325901 (100 nM), or combination BKM120 + PD0325901 (5 μM/100 nM) (upper panels), or control, BEZ235 (1000 nM), PD0325901 (100 nM), or combination BEZ235 + PD0325901 (1000 nM/100 nM) (lower panels) and continued for 24 hours. Apoptosis was measured by DNA fragmentation using the Cell Death Detection ELISAplus (* p < 0.05 vs. control; � p < 0.05 vs. monotherapy). (C) BON cells were plated in 6 well plates at 9 x 105 cells/well. After 24h of treatment, cells were collected, stained with annexin V Alexa Fluor 488, and analyzed by flow cytometry (* p < 0.05 vs. control; � p < 0.05 vs. monotherapy).
Supplementary Figure 4 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Authors: Valentino Joseph D. , Li Jing , Zaytseva Yekaterina Y. , Mustain W. Conan , Elliott Victoria A. , Kim Ji Tae , Harris Jennifer W. , Campbell Katherine , Weiss Heidi , Wang Chi , Song Jun , Anthony Lowell , Townsend Courtney M. , Evers B. Mark
Published: April 2023

PDF file - 649KB, Combination PI3K and MEK inhibitor treatment results in a more pronounced decrease in NCI-H727 and QGP-1 cell proliferation. (A) NCI-H727 and (B) QGP-1 cells were plated in 24 well plates at a density of 3x104 cells/well. Treatments were initiated the following morning with either control, BKM120 (5 μM), PD0325901 (100 nM), or combination BKM120 + PD0325901 (5 μM/100 nM) (upper panels), or control, BEZ235 (1000 nM), PD0325901 (100 nM), or combination BEZ235 + PD0325901 (1000 nM/100 nM) (lower panels). Media was exchanged for fresh drug media at 36h. Proliferation was assessed directly by cell counting at 72h (* p < 0.05 vs. control; � p < 0.05 vs. monotherapy).
Supplementary Figure 2 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Authors: Valentino Joseph D. , Li Jing , Zaytseva Yekaterina Y. , Mustain W. Conan , Elliott Victoria A. , Kim Ji Tae , Harris Jennifer W. , Campbell Katherine , Weiss Heidi , Wang Chi , Song Jun , Anthony Lowell , Townsend Courtney M. , Evers B. Mark
Published: April 2023

PDF file - 812 KB, PI3K inhibition decreases cell proliferation in NCI-H727 and QGP-1 cell lines. (A) NCI-H727 and (B) QGP-1 cells were plated in 24 well plates at a density of 3x104 cells/well. Treatments were initiated the following morning with increasing doses of either BKM120 (0-5 μM) (upper panels) or BEZ235 (0-1000 nM) (lower panels). Media was exchanged for fresh drug media again at 36h. Proliferation was assessed directly by cell counting at 72h (* p < 0.05 vs. control). (C) BON cells transfected with shRNA directed against the alpha subunit of PI3K were plated in 24 well plates at a density of 3x104 cells/well and proliferation assessed at 24h intervals up to 96h.
Supplementary Figure 5 from Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors
Authors: Wu Chao-Yi , Yang Li-Hua , Yang Huang-Yu , Knoff Jayne , Peng Shiwen , Lin Yi-Hsin , Wang Chenguang , Alvarez Ronald D. , Pai Sara I. , Roden Richard B.S. , Hung Chien-Fu , Wu T-C
Published: April 2023

PDF file - 809K, Evaluation of antitumor effect after radiation combined with intratumoral E7 peptide treatment in TLR9-/- and WT C57BL/6 mice.
Supplementary Figure 1 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Authors: Valentino Joseph D. , Li Jing , Zaytseva Yekaterina Y. , Mustain W. Conan , Elliott Victoria A. , Kim Ji Tae , Harris Jennifer W. , Campbell Katherine , Weiss Heidi , Wang Chi , Song Jun , Anthony Lowell , Townsend Courtney M. , Evers B. Mark
Published: April 2023

PDF file - 1864KB, mTOR inhibition decreases proliferation but does not increase apoptosis or enhance effect in combination with a MEK inhibitor. (A) BON, (B) NCI-H727 and (C) QGP-1 cells were plated in 24 well plates at a density of 3x104 cells/well. Treatments were initiated the following morning with either control, rapamycin (20 nM), PIK-75 (1 μM), PD98059 (10 μM), rapaymycin + PD98059 (20 nM/10 μM), or PIK-75 + PD98059 (1 μM /10 μM). Proliferation (upper panels) was assessed directly by cell counting at 72h (* p < 0.05 vs. control; � p < 0.05 vs. monotherapy). Apoptosis (middle panels) was measured by DNA fragmentation using the Cell Death Detection ELISAplus (* p < 0.05 vs. control; � p < 0.05 vs. monotherapy). For Western blot analysis (lower panels), cells were plated in 6 well plates at a density of 5 x104 cells/cm2. Whole cell lysates were collected following 24h of drug treatment. β-actin was used as a loading control.
Supplementary Figure 3 from Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors
Authors: Wu Chao-Yi , Yang Li-Hua , Yang Huang-Yu , Knoff Jayne , Peng Shiwen , Lin Yi-Hsin , Wang Chenguang , Alvarez Ronald D. , Pai Sara I. , Roden Richard B.S. , Hung Chien-Fu , Wu T-C
Published: April 2023

PDF file - 919K, Characterization of antitumor effect in WF3 tumor-bearing mice treated with radiation and E7 peptide.
Supplementary Methods from Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
Authors: Li Li , Han Rui , Xiao Hualiang , Lin Caiyu , Wang Yubo , Liu Hao , Li Kunlin , Chen Hengyi , Sun Fenfen , Yang Zhenzhou , Jiang Jianxin , He Yong
Published: April 2023

PDF file - 103K
Supplementary Figure Legends from Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
Authors: Li Li , Han Rui , Xiao Hualiang , Lin Caiyu , Wang Yubo , Liu Hao , Li Kunlin , Chen Hengyi , Sun Fenfen , Yang Zhenzhou , Jiang Jianxin , He Yong
Published: April 2023

PDF file - 119K
Supplementary Figure 1 from Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors
Authors: Wu Chao-Yi , Yang Li-Hua , Yang Huang-Yu , Knoff Jayne , Peng Shiwen , Lin Yi-Hsin , Wang Chenguang , Alvarez Ronald D. , Pai Sara I. , Roden Richard B.S. , Hung Chien-Fu , Wu T-C
Published: April 2023

PDF file - 1324K, Schematic diagram of the potential mechanisms of immune mediated antitumor effects as a result of intratumor peptide delivery following radiation.
Supplementary Figure 1 from EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma
Authors: Behrens Carmen , Solis Luisa M. , Lin Heather , Yuan Ping , Tang Ximing , Kadara Humam , Riquelme Erick , Galindo Hector , Moran Cesar A. , Kalhor Neda , Swisher Stephen G. , Simon George R. , Stewart David J. , Lee J. Jack , Wistuba Ignacio I.
Published: April 2023

PDF file 106K, Kaplan-Meir curves depicting recurrence-free survival rates in the two sets of lung adenocarcinoma patients by EZH2 and combined EZH2/TTF-1 expressions
Supplementary Figure Legend, Methods from The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors
Authors: Juliachs M. , Muñoz C. , Moutinho C.A. , Vidal A. , Condom E. , Esteller M. , Graupera M. , Casanovas O. , Germà J.R. , Villanueva A. , Viñals F.
Published: April 2023

PDF file - 83K
Supplementary Figure 1 from The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors
Authors: Juliachs M. , Muñoz C. , Moutinho C.A. , Vidal A. , Condom E. , Esteller M. , Graupera M. , Casanovas O. , Germà J.R. , Villanueva A. , Viñals F.
Published: April 2023

PDF file - 242K, In Figure S1 we present the results obtained on PDGFR expression analysis by flow cytometry, were we show how this receptor is expressed in the cell surface at higher levels in GCT27R cells than in GCT27S cells.
Supplementary Figure 6 from Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number
Authors: De Cesare Michelandrea , Lauricella Calogero , Veronese Silvio Marco , Cominetti Denis , Pisano Claudio , Zunino Franco , Zaffaroni Nadia , Zuco Valentina
Published: April 2023

PDF file - 75K, Effect of p38 inhibition on cell proliferation of A431 cells exposed to cetuximab alone (0.5microg/ml) or plus namitecan (0.01microM) for 72 h.
Supplementary Figure Legends from Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Authors: Rexer Brent N. , Ghosh Ritwik , Narasanna Archana , Estrada Mónica Valeria , Chakrabarty Anindita , Song Youngchul , Engelman Jeffrey A. , Arteaga Carlos L.
Published: April 2023

Supplementary Figure Legends - PDF file 98K, Legends for supplementary figures 1-7
Supplementary Figure 5 from Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Authors: Rexer Brent N. , Ghosh Ritwik , Narasanna Archana , Estrada Mónica Valeria , Chakrabarty Anindita , Song Youngchul , Engelman Jeffrey A. , Arteaga Carlos L.
Published: April 2023

Supplementary Figure 5 - PDF file 77K, HER3 expression is required for growth of T798M mutant-expressing cells
Supplementary Figure 3 from Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Authors: Rexer Brent N. , Ghosh Ritwik , Narasanna Archana , Estrada Mónica Valeria , Chakrabarty Anindita , Song Youngchul , Engelman Jeffrey A. , Arteaga Carlos L.
Published: April 2023

Supplementary Figure 3 - PDF file 66K, Dilutional cloning of T798M shows mutant expression in 3% of alleles
Supplementary Figure 2 from Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
Authors: Fransen Marieke F. , van der Sluis Tetje C. , Ossendorp Ferry , Arens Ramon , Melief Cornelis J.M.
Published: April 2023

PDF file - 24K, T cell responses in tumor and Tumor-draining LN.
CCR Translation for This Article from Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
Authors: Fransen Marieke F. , van der Sluis Tetje C. , Ossendorp Ferry , Arens Ramon , Melief Cornelis J.M.
Published: April 2023

CCR Translation for This Article from Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
Supplementary Figure 1E from Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
Authors: Sidhu Roger , Rong Alan , Dahlberg Steve
Published: April 2023

PDF file - 44 KB, Trials with anti-epidermal growth factor receptor (EGFR) therapy
Supplementary Information from MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer
Authors: Kaur Sukhwinder , Sharma Neil , Krishn Shiv Ram , Lakshmanan Imay , Rachagani Satyanarayana , Baine Michael J. , Smith Lynette M. , Lele Subodh M. , Sasson Aaron R. , Guha Sushovan , Mallya Kavita , Anderson Judy M. , Hollingsworth Michael A. , Batra Surinder K.
Published: April 2023

PDF file 98K, Supplementary Methodology
Supplementary Figure 1D from Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
Authors: Sidhu Roger , Rong Alan , Dahlberg Steve
Published: April 2023

PDF file - 44 KB, First-line phase III trials with targeted therapies
Supplementary Fig. 3 from MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer
Authors: Kaur Sukhwinder , Sharma Neil , Krishn Shiv Ram , Lakshmanan Imay , Rachagani Satyanarayana , Baine Michael J. , Smith Lynette M. , Lele Subodh M. , Sasson Aaron R. , Guha Sushovan , Mallya Kavita , Anderson Judy M. , Hollingsworth Michael A. , Batra Surinder K.
Published: April 2023

PDF file 80K, Lipocalin 2 levels in response to surgery
Supplementary Fig. 2 from MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer
Authors: Kaur Sukhwinder , Sharma Neil , Krishn Shiv Ram , Lakshmanan Imay , Rachagani Satyanarayana , Baine Michael J. , Smith Lynette M. , Lele Subodh M. , Sasson Aaron R. , Guha Sushovan , Mallya Kavita , Anderson Judy M. , Hollingsworth Michael A. , Batra Surinder K.
Published: April 2023

PDF file 130K, Inhibition of lipocalin 2 by Bay11-7082